Valuation: Cann Group Limited

Market Cap 8.3M 5.86M 5.07M 4.74M 4.35M 8.17M 558M 55.58M 21.81M 280M 22.02M 21.54M 925M P/E 2024
-0.23x
P/E 2025 -0.24x
Enterprise Value 84.13M 59.42M 51.4M 48M 44.03M 82.82M 5.66B 563M 221M 2.83B 223M 218M 9.37B EV / Sales 2024
4.54x
EV / Sales 2025 6.2x
Free-Float
82.48%
Yield 2024 *
-
Yield 2025 -
1 week+20.00%
Current month+20.00%
1 month-25.00%
3 months-40.00%
6 months-62.50%
Current year-66.67%
1 week 0
Extreme 0.003
0
1 month 0
Extreme 0.002
0
Current year 0
Extreme 0.002
0.01
1 year 0
Extreme 0.002
0.02
3 years 0
Extreme 0.002
0.19
5 years 0
Extreme 0.002
0.44
10 years 0
Extreme 0.002
4.55
Manager TitleAgeSince
Chief Executive Officer - 01/04/2024
Director of Finance/CFO - 14/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 79 10/02/2025
Director/Board Member - 08/09/2020
Director/Board Member 59 31/03/2025
Date Insider Type Main position Quantity % Market Cap.
12/06/24 Buy

Chief Executive Officer

205,500 0.0469%
01/08/23 Buy

Director

165,515 0.0341%
01/08/23 Buy

Chairman

284,091 0.0585%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+20.00%-76.92%-97.50% 3.52M
+1.96%+8.33%+20.93%+243.80% 238M
+0.74%+4.58%-30.81%-28.65% 138M
-0.52%+3.23%+1.05%+74.55% 136M
+1.25%+3.85%-20.59%-37.69% 82.2M
+3.97%-6.06%-40.69%-53.31% 53.97M
Average +1.23%+5.65%-24.50%+16.87% 108.65M
Weighted average by Cap. +1.25%+4.78%-5.07%+88.70%

Financials

2024 2025
Net sales 18.36M 12.97M 11.22M 10.47M 9.61M 18.07M 1.23B 123M 48.23M 618M 48.69M 47.62M 2.04B 13.25M 9.36M 8.1M 7.56M 6.94M 13.05M 891M 88.71M 34.82M 447M 35.15M 34.38M 1.48B
Net income -51.24M -36.19M -31.3M -29.23M -26.82M -50.44M -3.44B -343M -135M -1.73B -136M -133M -5.71B -22.34M -15.78M -13.65M -12.75M -11.69M -22M -1.5B -150M -58.7M -753M -59.26M -57.97M -2.49B
Net Debt 70.83M 50.02M 43.27M 40.41M 37.07M 69.72M 4.76B 474M 186M 2.39B 188M 184M 7.89B 75.83M 53.56M 46.33M 43.26M 39.69M 74.64M 5.1B 508M 199M 2.55B 201M 197M 8.45B
Logo Cann Group Limited
Cann Group Limited is an Australia-based company, which is focused on developing, producing, and supplying innovative cannabis medicines. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the Company, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. It operates through cultivation of the medicinal cannabis segment. The Company supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. It also owns Satipharm and its patent-protected capsule technology. The Company's research and good manufacturing practices (GMP) manufacturing facilities are near Mildura, Victoria.
Employees
-
Date Price Change Volume
07/08/26 A$0.003000 0.00% 526,720
06/08/26 A$0.003000 0.00% 2,406,376
05/08/26 A$0.003000 0.00% 353,939
04/08/26 A$0.003000 0.00% 827,142
03/08/26 A$0.003000 +20.00% 6,698,436